A clinical trial of gene therapy for chronic pain

Pain Medicine

Volumn 10, Issue 7, 2009, Pages 1325-1330

  Wolfe, Darren ^a   Wechuck, James ^a   Krisky, David ^a   Mata, Marina ^b   Fink, David J ^b  

^a Diamyd Inc   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Neurology; Pain Management; Persistent Pain; Therapy

Indexed keywords

GLUTAMATE DECARBOXYLASE; PREPROENKEPHALIN; VIRUS VECTOR;

ARTICLE; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HUMAN; INTRACTABLE PAIN; NEUROPATHIC PAIN; NONHUMAN; SPINAL GANGLION; CHRONIC DISEASE; GENETICS; METHODOLOGY; PAIN; REVIEW; TREATMENT OUTCOME;

CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; PAIN; TREATMENT OUTCOME;

EID: 73949111798     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00720.x     Document Type: Article

References (29)

1. Schug S, Gandham N. Opioids: Clinical use. Textbood of Pain 2006, 443-58. McMahon SB, Koltzenburg M. eds., New York/Amsterdam, Elsevier
2. Dickenson AH, Kieffer BL. Opiates: Basic mechanisms. Textbook of Pain 2006, 427-42. McMahon SB, Koltzenburg M. eds., New York/Amsterdam, Elsevier
3. Mata M, Hao S, Fink DJ. Applications of gene therapy to the treatment of chronic pain. Curr Gene Ther 2008, 8:42-8.
4. Roizman B, Knipe DM. Herpes simplex viruses and their replication. Fields Virology 2001, 2399-460. Knipe DM, Howley PM. eds., Philadelphia, PA, Lippincott Williams & Wilkins
5. Wolfe D, Goins WF, Yamada M. Engineering herpes simplex virus vectors for CNS applications. Exp Neurol 1999, 159:34-46.
6. Glorioso JC, Fink DJ. Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu Rev Microbiol 2004, 58:253-71.
7. Goss JR, Harley CF, Mata M. Herpes vector-mediated expression of proenkephalin reduces pain-related behavior in a model of bone cancer pain. Ann Neurol 2002, 52:662-5.
8. Antunes Bras JM, Epstein AL, Bourgoin S. Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem 1998, 70:1299-303.
9. Braz J, Beaufour C, Coutaux A. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci 2001, 21:7881-8.
10. Meunier A, Latremoliere A, Mauborgne A. Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther 2005, 11:608-16.
11. Hao S, Mata M, Goins W, Glorioso JC, Fink DJ. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect. Pain 2003, 102:135-42.
12. Chattopadhyay M, Mata M, Fink DJ. Continuous delta opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1. 7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci 2008, 28:6652-8.
13. Baba H, Ji RR, Kohno T. Removal of GABAergic inhibition facilitates polysynaptic A fiber-mediated excitatory transmission to the superficial spinal dorsal horn. Mol Cell Neurosci 2003, 24:818-30.
14. Scholz J, Broom DC, Youn DH. Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J Neurosci 2005, 25:7317-23.
15. Liu J, Wolfe D, Hao S. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther 2004, 10:57-66.
16. Liu J, Tai C, de Groat WC. Release of GABA from sensory neurons transduced with a GAD67-expressing vector occurs by non-vesicular mechanisms. Brain Res 2006, 1073(4):297-304.
17. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50:355-63.
18. Hao S, Mata M, Wolfe D, Glorioso JC, Fink DJ. Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol 2005, 57:914-18.
19. Wolfe D, Mata M, Fink DJ. A human trial of HSV-mediated gene transfer for the treatment of chronic pain. Gene Ther 2009, 16:455-60.
20. Melzack R. Pain Measurement and Assessment 1983, New York, Raven Press
21. Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-55.
22. Wolfe D, Hao S, Hu J. Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain 2007, 133:29-38.
23. Yeomans DC, Levinson SR, Peters MC. Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents. Hum Gene Ther 2005, 16:271-7.
24. Hao S, Mata M, Glorioso JC, Fink DJ. HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain 2006, 2:6.
25. Zhou Z, Peng X, Hao S, Fink DJ, Mata M. HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther 2008, 15:183-90.
26. Peng X, Zhou Z, Glorioso JC, Fink DJ, Mata M. Tumor necrosis factor alpha contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol 2006, 59:843-51.
27. Hao S, Mata M, Glorioso JC, Fink DJ. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther 2007, 14:1010-6.
28. Mata M, Hao S, Fink DJ. Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNFalpha. Neurosci Lett 2008, 437:209-13.
29. Srinivasan R, Wolfe D, Goss J. Protein kinase C epsilon contributes to basal and sensitizing responses of TRPV1 to capsaicin in rat dorsal root ganglion neurons. Eur J Neurosci 2008, 28:1241-54.